Zynerba Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ZYNE Zynerba Pharmaceuticals Inc
BWEN Broadwind Inc
EQIX Equinix Inc
TXMD TherapeuticsMD Inc
ORC Orchid Island Capital Inc
GBX Greenbrier Companies Inc
FCX Freeport-McMoRan Inc
TRKA Troika Media Group Inc
SXTC China SXT Pharmaceuticals Inc
NLTX Neoleukin Therapeutics Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The Company is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. It has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Price
Delayed
$1.35
Day's Change
0.15 (12.50%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.37
Day's Low
1.21
Volume
(Heavy Day)

Today's volume of 370,436 shares is on pace to be much greater than ZYNE's 10-day average volume of 409,463 shares.

370,436

Display:

Providers:

UpdateCancel
6 providers
Today's News, August 10, 2022
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel(TM) in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients...(Globe Newswire)

August 03, 2022
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference

EQNX::TICKER_START (NasdaqGM:ZYNE), EQNX::TICKER_END Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that...(Globe Newswire)

July 21, 2022
Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

EQNX::TICKER_START (NasdaqGM:ZYNE), EQNX::TICKER_END Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced it has...(Globe Newswire)

July 07, 2022
Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference

EQNX::TICKER_START (NasdaqGM:ZYNE), EQNX::TICKER_END Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today...(Globe Newswire)

June 21, 2022
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel(TM) in 22q11.2 Deletion Syndrome

EQNX::TICKER_START (NasdaqGM:ZYNE), EQNX::TICKER_END - The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments - - Safety data reinforce excellent tolerability...(Globe Newswire)

June 16, 2022
Thailand Becomes First Asian Country to Legalize Marijuana

FN Media Group Presents Microsmallcap.com Market Commentary Thailand made headlines last week when it became the first country in Asia to decriminalize marijuana, making it legal to grow and sell or use for medicinal reasons. Thai Health Minister...(PR Newswire)

June 01, 2022
Zynerba Pharmaceuticals Presents Data on Zygel(TM) at the American Society of Clinical Psychopharmacology Annual Meeting

EQNX::TICKER_START (NasdaqGM:ZYNE), EQNX::TICKER_END - Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial - - Oral presentation demonstrates long-term safety and potential effectiveness of Zygel in children...(Globe Newswire)

May 24, 2022
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

EQNX::TICKER_START (NasdaqGM:ZYNE), EQNX::TICKER_END Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today...(Globe Newswire)

May 17, 2022
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

EQNX::TICKER_START (NasdaqGM:ZYNE), EQNX::TICKER_END Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today...(Globe Newswire)

May 16, 2022
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

EQNX::TICKER_START (NasdaqGM:ZYNE), EQNX::TICKER_END - Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel(TM) in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 - (Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.